You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》里昂升中生制药(01177.HK)目标价至9.18元评级「买入」
阿思达克 06-19 10:34

里昂发表报告指,中生制药(01177.HK)公布其附属正大天晴与中山康方生物医药成立合营,共同开发重组人源化抗PD-1单克隆抗体AK105项目,并推动该药物的注册上市及产业化进程。该行对是次合作持正面态度,并预期上述抗体不仅可成下一重磅药物,而且还可通过混合使用以延长集团肺癌药物「Anlotinib」的产品周期。

里昂上调对中生制药的股份目标价,由8.84元升至9.18元,评级维持「买入」。该行估计,是次合营在2021年至2023年可开始有入账销售分别10亿元、15亿元及18亿元人民币,经调整盈利则可分别上升3.1%、3.2%及3%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account